TLR3 and cancer: On the one hand, the TLR3 signal sequentially activated IRF3 and NF‐κB after poly I:C (a TLR3 agonist) stimulation, which resulted in the release of IL‐6 and C‐C motif chemokine ligand 5(CCL5), as well as the enhancement of cancer cell migration.